In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage in the booming weight-loss drug market. Competitor Novo Nordisk has fallen behind Lilly, as Lilly’s weight-loss shot Zepbound has seized a commanding majority of U.S. obesity prescriptions over Novo’s Wegovy.

Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook.